Literature DB >> 15979222

The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s).

Michael A Dorato1, Jeffery A Engelhardt.   

Abstract

The no-observed-adverse-effect-level (NOAEL) is an important part of the non-clinical risk assessment. It is a professional opinion based on the design of the study, indication of the drug, expected pharmacology, and spectrum of off-target effects. There is no consistent standard definition of NOAEL. This is based, in part, on the varied definitions of what constitutes an adverse effect. Toxicologists, either investigating or reviewing, have not been consistent in defining an effect as either adverse or acceptable. The common definition of NOAEL, "the highest experimental point that is without adverse effect," serves us well in general discussions. It does not, however, address the interpretation of risk based on toxicologically relevant effects, nor does it consider the progression of effect with respect to duration and/or dose. This paper will discuss the issues and application of a functional definition of the NOAEL in toxicology evaluations.

Mesh:

Substances:

Year:  2005        PMID: 15979222     DOI: 10.1016/j.yrtph.2005.05.004

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  25 in total

1.  Identification and characterization of adverse effects in 21st century toxicology.

Authors:  Douglas A Keller; Daland R Juberg; Natasha Catlin; William H Farland; Frederick G Hess; Douglas C Wolf; Nancy G Doerrer
Journal:  Toxicol Sci       Date:  2012-01-19       Impact factor: 4.849

2.  A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target.

Authors:  Ajay D Pillai; Margaret Pain; Tsione Solomon; Abdullah A B Bokhari; Sanjay A Desai
Journal:  Mol Pharmacol       Date:  2010-01-25       Impact factor: 4.436

3.  Model-based prediction of the acute and long-term safety profile of naproxen in rats.

Authors:  Tarjinder Sahota; Ian Sanderson; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Pharmacol       Date:  2015-06-29       Impact factor: 8.739

4.  Is It Adverse, Nonadverse, Adaptive, or Artifact?

Authors:  Arun R Pandiri; Roy L Kerlin; Peter C Mann; Nancy E Everds; Alok K Sharma; L Peyton Myers; Thomas J Steinbach
Journal:  Toxicol Pathol       Date:  2016-10-23       Impact factor: 1.902

5.  TinderMIX: Time-dose integrated modelling of toxicogenomics data.

Authors:  Angela Serra; Michele Fratello; Giusy Del Giudice; Laura Aliisa Saarimäki; Michelangelo Paci; Antonio Federico; Dario Greco
Journal:  Gigascience       Date:  2020-05-01       Impact factor: 6.524

6.  Preclinical Evaluation of Safety and Biodistribution of Red Cell Microparticles: A Novel Hemostatic Agent.

Authors:  Ashish K Rehni; Vibha Shukla; Hever Navarro Quero; Carlos Bidot; Conner R Haase; Ensign Anise A Crane; Shivam G Patel; Sebastian Koch; Yeon S Ahn; Wenche Jy; Kunjan R Dave
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-04-29       Impact factor: 2.457

7.  Retrospective mining of toxicology data to discover multispecies and chemical class effects: Anemia as a case study.

Authors:  Richard S Judson; Matthew T Martin; Grace Patlewicz; Charles E Wood
Journal:  Regul Toxicol Pharmacol       Date:  2017-02-24       Impact factor: 3.271

8.  Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.

Authors:  Aaron R Hansen; Natalie Cook; M Stacey Ricci; Albiruni Razak; Christophe Le Tourneau; Kathleen McKeever; Lorin Roskos; Rakesh Dixit; Lillian L Siu; Mary Jane Hinrichs
Journal:  Oncologist       Date:  2015-05-11

9.  Metabolic profiling of Lolium perenne shows functional integration of metabolic responses to diverse subtoxic conditions of chemical stress.

Authors:  Anne-Antonella Serra; Ivan Couée; David Renault; Gwenola Gouesbet; Cécile Sulmon
Journal:  J Exp Bot       Date:  2015-01-24       Impact factor: 6.992

10.  Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

Authors:  Jostein Dahle; Thora J Jonasdottir; Helen Heyerdahl; Jahn M Nesland; Jørgen Borrebaek; Anne Kristine Hjelmerud; Roy H Larsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.